SCHEMBL6434895

SCHEMBL6434895

NN=C(c1ccc(-c2cccc(C(=O)O)c2)o1)c1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.45
MAPT P10636 5/20 0.41
POLB P06746 5/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 4/20 0.41
TDP1 Q9NUW8 3/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
NR4A1 P22736 1/20 0.39
NR4A2 P43354 1/20 0.39
NR4A3 Q92570 1/20 0.39
VCP P55072 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
LDHA P00338 4/20 0.37
LCK P06239 1/20 0.36
CSNK2A1 P68400 1/20 0.36
RAB9A P51151 1/20 0.36
SLC9A1 P19634 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419710 0.93 MAPT (0.40) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6413428 0.93 BIRC5 (0.47) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6419745 0.90 PTPN1 (0.43) MAPTPOLBALDH1A1KDM4ETDP1
SCHEMBL6415959 0.90 BIRC5 (0.42) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6419747 0.88 BIRC5 (0.43) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6419244 0.87 BIRC5 (0.48) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6431830 0.87 BIRC5 (0.44) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6415907 0.87 BIRC5 (0.41) BIRC5MAPTPOLBALDH1A1KDM4E
SCHEMBL6433045 0.85 KDM4E (0.45) MAPTPOLBALDH1A1KDM4ETDP1
SCHEMBL6414854 0.83 BIRC5 (0.65) BIRC5MAPTPOLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885MAPT 4420/4885POLB 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.